Lipids & metabolic liver disease
Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease
Authors' conclusion
Our study highlights the clinical value of TyG-related indices in predicting the survival of the NAFLD/MASLD population. TyG-BMI and TyG-WC indices would be the surrogate biomarkers for the follow-up of the population without advanced fibrosis.
Study context
- Population
- Participants with non-alcoholic fatty liver disease (NAFLD) or MASLD in NHANES III with completed ultrasonography and laboratory data; mortality followed through 31 December 2019NAFLD 3672
- Participants
- 10,390 participants
- Exposure
- Levels of triglyceride-glucose (TyG)-related indices
- Outcome
- All-cause, cardiovascular and diabetes mortality
- Follow-up
- Through 31 December 2019
Methodological detailsNHANES III linked to National Death Index, multivariate Cox and restricted cubic spline regression
- NHANES III linked to National Death Index
- Multivariate Cox and restricted cubic spline regression
Main finding
As reported in the abstract
Mortality by TyG-related indices in NAFLD/MASLD
- High TyG-related indices, particularly TyG-BMI and TyG-WC, significantly associated with all-cause, cardiovascular and diabetes mortality in either NAFLD or MASLD
- Nonlinear trend between the three TyG-related indices and all-cause mortality in either NAFLD or MASLD (restricted cubic spline (RCS))
- Multivariate Cox regression
Observational data: associations, not effects.
Further findings
NAFLD prevalence in overall population
- NAFLD
- 3672/10,390 (35.3%)
- MASLD
- 3556/10,390 (34.2%)
All-cause mortality by subgroup (age, sex, race/ethnicity, FIB-4)
- TyG-BMI and TyG-WC more suitable for predicting all-cause mortality in patients without advanced fibrosis
Original publication
Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol. Published 4 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →